Clinical trial ZEN003694-004
A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Zenith Epigenetics Ltd. |
| EudraCT Identifier | 2018-003906-26 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03901469 |
| Inclusion criteria | Triple-negative breast cancer |
| Last update |